RWM
TGTX icon

Rialto Wealth Management’s TG Therapeutics TGTX Stock Holding History

Rialto Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Buy
26
+10
+63% +$409 ﹤0.01% 1233
2026
Q1 		$532 Buy
16
+12
+300% +$358 ﹤0.01% 1337
2025
Q4 		$120 Buy
+4
New +$131 ﹤0.01% 1608

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Rialto Wealth Management's TGTX Position: Q2 2026 in Review

Rialto Wealth Management increased its TG Therapeutics (TGTX) stake by 63% in Q2 2026, buying an estimated $409 and bringing the position to 26 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Rialto Wealth Management first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Rialto Wealth Management held 26 shares of TG Therapeutics worth $1.43K as of Q2 2026.
  • Rialto Wealth Management bought 10 TG Therapeutics shares in Q2 2026, an estimated $409.
  • TG Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1233 holding.
  • Rialto Wealth Management first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.